AI-Driven Breakthrough in Metabolic Disease Therapy: Eli Lilly and insitro Forge Strategic Collaboration

On October 9, 2024, local time, Eli Lilly and Company and insitro Inc. announced three strategic agreements to jointly advance new therapies for metabolic diseases, particularly Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). This collaboration highlights the significant potential of AI in drug development.

Metabolic diseases, such as MASLD, affect a large population worldwide, but effective treatment options remain limited.Traditional therapies only alleviate symptoms in MASLD patients and fail to address the root cause.This collaboration between Eli Lilly and insitro aims to combine insitro's machine learning platform with Eli Lilly's expertise in cutting-edge drug delivery and metabolic disease biology to provide transformative treatment options for patients with metabolic diseases.

Under the agreement, insitro has the option to license Eli Lilly and Company's proprietary clinical-stage tripartite N-acetylgalactosamine (GalNAc) delivery technology for its two liver-targeted siRNA therapies in development.In addition, the two parties will also collaborate to develop antibody therapies targeting new metabolic disease targets.In the collaboration, insitro retains global rights to the program, while Eli Lilly and Company is eligible for potential milestone payments and royalties.

Unlike other AI-driven drug discovery deals, the asset flow in this collaboration between Eli Lilly and insitro is reversed.Typically, startups license technology or drugs to pharmaceutical giants, but in this collaboration, insitro has obtained a clinical-stage dosing method license from Eli Lilly and Company.

With this deal, insitro joins the growing list of AI startups actively exploring partnerships with large pharmaceutical companies to produce better drugs.For example, in June 2024, Eli Lilly and Company signed a partnership with OpenAI specifically to address drug-resistant infections.Antimicrobial Resistance (AMR) is one of the major public health challenges facing the globe, and Eli Lilly and Company plans to use OpenAI's generative artificial intelligence technology to develop novel microbial agents for pathogens.

At the same time, Flagship Pioneering's Generate:Biomedicines received a $65 million upfront payment from pharmaceutical giant Novartis last month, along with commitments for performance-based milestones and royalties, in a deal worth up to $1 billion.Although the partner has not yet disclosed the priority targets or therapeutic areas of interest, this collaboration also demonstrates the tremendous value of AI in drug discovery.